Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 45 entries
View as:

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005871 Org: User:
Start: 11/30/98 End: - Due: -

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Phase: N/A Priority: Normal
NCT ID: NCT01294202 Org: User:
Start: 03/31/11 End: 07/31/14 Due: 07/31/15

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00878423 Org: User:
Start: 05/31/08 End: 03/31/14 Due: 03/31/15

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Phase: N/A Priority: Normal
NCT ID: NCT01685268 Org: User:
Start: 09/30/12 End: 12/31/14 Due: 12/31/15

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00005875 Org: User:
Start: 01/31/99 End: 04/30/04 Due: 04/30/05

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00894894 Org: User:
Start: 05/31/07 End: 12/31/08 Due: 12/31/09

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005869 Org: User:
Start: 11/30/98 End: - Due: -

Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04479800 Org: User:
Start: 07/20/20 End: 08/25/20 Due: 08/25/21

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00005870 Org: User:
Start: 03/31/99 End: - Due: -

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02920008 Org: User:
Start: 03/16/17 End: 06/01/20 Due: 06/01/21

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Phase: N/A Priority: Normal
NCT ID: NCT02907359 Org: User:
Start: 01/13/17 End: 11/30/20 Due: 11/30/21

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Phase: N/A Priority: Normal
NCT ID: NCT00041990 Org: User:
Start: 07/31/02 End: - Due: -

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Phase: N/A Priority: Normal
NCT ID: NCT01712217 Org: User:
Start: 10/31/12 End: 05/16/17 Due: 05/16/18

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01183949 Org: User:
Start: 11/30/10 End: 03/31/15 Due: 03/31/16

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00504205 Org: User:
Start: 05/31/07 End: 03/31/10 Due: 03/31/11

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Phase: N/A Priority: Normal
NCT ID: NCT03306264 Org: User:
Start: 02/15/18 End: 05/25/23 Due: 05/25/24

Guadecitabine Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03603964 Org: User:
Start: 07/18/18 End: 10/04/21 Due: 10/04/22

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04953923 Org: User:
Start: 07/01/21 End: 11/16/21 Due: 11/16/22

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00113256 Org: User:
Start: 02/28/05 End: - Due: -

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Phase: N/A Priority: Normal
NCT ID: NCT04466514 Org: User:
Start: 07/23/20 End: 10/06/20 Due: 10/06/21

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT02103478 Org: User:
Start: 10/28/14 End: 12/04/19 Due: 12/04/20

SGI-110 in Combination With Carboplatin in Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01696032 Org: User:
Start: 09/30/12 End: 08/31/16 Due: 08/31/17

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT01752933 Org: User:
Start: 12/31/12 End: 09/30/15 Due: 09/30/16

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00113113 Org: User:
Start: 08/31/01 End: - Due: -

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Phase: N/A Priority: Normal
NCT ID: NCT02348489 Org: User:
Start: 03/19/15 End: 06/17/19 Due: 06/17/20